Rani Therapeutics to present at Canaccord Genuity Annual Growth ConferencePUBT·17 hours agoRANI-1.91%
Rani Therapeutics names Michelle Gilson to board as audit committee chairPUBT·Aug 4 at 07:01 AMRANI-1.91%GILD-0.11%
Rani Therapeutics director, 10% owner Mir A. Imran buys 36,000 shares worth $24,840PUBT·Jul 23 at 03:11 PMRANI-1.91%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 22 at 12:05 PMCPHI-0.88%PMI+6.12%
Rani Therapeutics CEO Imran Talat acquires 35,000 shares worth $25,193PUBT·Jul 21 at 05:29 PMRANI-1.91%
Rani Therapeutics grants CFO Nicholas Maestas option for 2 million shares at $0.7 exercise pricePUBT·Jul 20 at 03:05 PMRANI-1.91%
Rani Therapeutics says oral RT-114 obesity drug candidate tops matched injection exposure in Phase 1a dataPUBT·Jul 15 at 07:01 AMRANI-1.91%
Rani Therapeutics Maintained at Buy as Partnerships Highlight Underappreciated Pipeline; $11 Price Target ReaffirmedTip Ranks·Jul 13 at 10:35 AMRANI-1.91%4519
PegBio Teams with Rani Therapeutics to Pursue Oral Metabolic TherapiesTip Ranks·Jul 9 at 07:07 PM02565+1.12%RANI-1.91%
